Heerspink HJL, Oshima M, Zhang H, Li J, et al. Canagliflozin Reduces Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial. Am J Kidney Dis 2021 May 21. pii: S0272-6386(21)00626.
PMID: 34029680